Imperial College London
Alternate

ProfessorSimonTaylor-Robinson

Faculty of Engineering, Department of Electrical and Electronic Engineering

Visiting Professor
 
 
 
//

Contact

 

s.taylor-robinson

 
 
//

Location

 

Electrical EngineeringSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Ladep:2013:10.4172/2155-6113.S3-006,
author = {Ladep, NG and Agbaji, OO and Agaba, PA and Muazu, A and Ugoagwu, P and Imade, G and Cooke, GS and Vivas, L and Cormack, SM and Taylor-Robinson, SD and Idoko, J and Kanki, P},
doi = {10.4172/2155-6113.S3-006},
journal = {J AIDS Clin Res},
title = {Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa.},
url = {http://dx.doi.org/10.4172/2155-6113.S3-006},
volume = {Suppl 3},
year = {2013}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Hepatitis B has been reported to be high in HIV-infected African populations. However, the impact of this co-infection on the survival of HIV-infected Africans on long-term highly active antiretroviral therapy (HAART) remains poorly characterised. We investigated the impact of HBV/HIV co-infection on survival of HIV infected patients undergoing antiretroviral therapy in a West African population. METHODS: This was a clinic-based cohort study of HIV-infected adults enrolled in Nigeria, West Africa. Study subjects (9,758) were screened for hepatitis B and hepatitis C at HAART initiation. Kaplan-Meier survival and Cox proportional hazards models were used to estimate probability of survival and to identify predictors of mortality respectively, based on hepatitis B surface antigen status. All patients had signed an informed written consent before enrolment into the study; and we additionally obtained permission for secondary use of data from the Harvard institutional review board. RESULTS: Patients were followed up for a median of 41 months (interquartile range: 30-62 months) during which, 181 (1.9%) patients died. Most of the deaths; 143 (79.0%) occurred prior to availability of Tenofovir. Among those that were on antiretroviral therapy, hepatitis B co-infected patients experienced a significantly lower survival than HIV mono-infected patients at 74 months of follow up (94% vs. 97%; p=0.0097). Generally, hepatitis B co-infection: HBsAg-positive/HIV-positive (Hazards Rate [HR]; 1.5: 95% CI 1.09-2.11), co-morbid tuberculosis (HR; 2.2: 95% CI 1.57-2.96) and male gender (HR; 1.5: 95% CI 1.08-2.00) were significantly predictive of mortality. Categorising the patients based on use of Tenofovir, HBV infection failed to become a predictor of mortality among those on Tenofovir-containing HAART. CONCLUSIONS: HBsAg-positive status was associated with reduced survival and was an independent predictor of mortality in this African HIV cohort on HAART. However, Tenofovir
AU  - Ladep,NG
AU  - Agbaji,OO
AU  - Agaba,PA
AU  - Muazu,A
AU  - Ugoagwu,P
AU  - Imade,G
AU  - Cooke,GS
AU  - Vivas,L
AU  - Cormack,SM
AU  - Taylor-Robinson,SD
AU  - Idoko,J
AU  - Kanki,P
DO  - 10.4172/2155-6113.S3-006
PY  - 2013///
SN  - 2155-6113
TI  - Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa.
T2  - J AIDS Clin Res
UR  - http://dx.doi.org/10.4172/2155-6113.S3-006
UR  - https://www.ncbi.nlm.nih.gov/pubmed/25328814
UR  - http://hdl.handle.net/10044/1/19143
VL  - Suppl 3
ER  -
Download